Altrova Health Announces Proposed Debt Settlement

Altrova Health Inc. (CSE: ROVA) (OTCQB: ATVHF) (FSE: WF8) (" Altrova Health " or the " Company ") announces that it proposes to enter into debt settlement agreements with three consultants to settle aggregate indebtedness of C$215,000 through the issuance of an aggregate of 3,583,333 common shares of the Company (" Common Shares ") at a deemed price of $0.06 per share (the " Debt Settlement "). The Debt Settlement is intended to reduce the Company's outstanding liabilities and preserve cash for working capital purposes. Completion of the Debt Settlement remains subject to the receipt of all required regulatory approvals, including the approval of the Canadian Securities Exchange (the " CSE "), and the satisfaction of other customary closing conditions. The Common Shares issued pursuant to the Debt Settlement will be subject to a statutory hold period of four months and one day from the date of issuance, in accordance with applicable securities laws and the policies of the CSE. The securities referred to in this news release have not been, and will not be, registered under the United States Securities Act of 1933, as amended (the " U.S. Securities Act "), or any U.S. state securities laws, and may not be offered or sold in the United States absent registration under the U.S. Securities Act and applicable U.S. state securities laws or compliance with an applicable exemption from those registration requirements. This news release does not constitute an offer to sell or the solicitation of an offer to buy any securities in the United States, nor will there be any sale of the securities in any jurisdiction in which such offer, solicitation or sale would be unlawful. About Altrova Health Inc. Altrova Health Inc. (CSE: ROVA) (OTCQB: ATVHF) (FSE: WF8) is a Canadian public company building a growing portfolio of health solutions across detection, protection, treatment, and wellness. The Company's current product portfolio includes exclusive Canadian distribution rights for the NIRLAB SA (" NIRLAB ") NIRLIGHT drug analysis device, the O-Spray product line, and the rapid detection strip portfolio of its subsidiary Drug Lab 118 Ltd. For more information, please visit: www.altrovahealth.com For additional information, please contact: Geoff Benic Chief Executive Officer Altrova Health Inc. Email: [email protected] Phone: +1 647-880-7314 Website: www.altrovahealth.com The Canadian Securities Exchange has neither approved nor disapproved the contents of this news release. Neither the Canadian Securities Exchange nor its Market Regulator (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this news release. Cautionary Note Regarding Forward-Looking Statements This news release contains "forward-looking information" and "forward-looking statements" (collectively, "forward-looking information") within the meaning of applicable Canadian securities legislation. Forward-looking information is generally, but not always, identified by words such as "anticipate", "believe", "expect", "intend", "may", "plan", "propose", "should", "will" and similar expressions, or statements that certain events or conditions "may" or "will" occur. Forward-looking information in this news release includes, but is not limited to, statements regarding: the proposed completion, timing and terms of the Debt Settlement; the aggregate C$215,000 of indebtedness to be settled; the issuance of an aggregate of 3,583,333 Common Shares at a deemed issue price of C$0.06 per Common Share; the anticipated reduction of the Company's outstanding liabilities and preservation of cash for working capital purposes; and the receipt of CSE and other required approvals. Forward-looking information is based on management's current expectations and assumpt...